Impact of chemotherapy on activated protein C-dependent thrombin generation - Association with VTE occurrence

International Journal of Cancer

Volumn 133, Issue 5, 2013, Pages 1253-1258

  Roselli, Mario ^a   Ferroni, Patrizia ^b   Riondino, Silvia ^b   Mariotti, Sabrina ^a   Laudisi, Anastasia ^a   Vergati, Matteo ^a   Cavaliere, Francesco ^c   Palmirotta, Raffaele ^b   Guadagni, Fiorella ^b  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

^b IRCCS SAN RAFFAELE PISANA   (Italy)

^c MOLINETTE HOSPITAL   (Italy)

Author keywords

chemotherapy; thrombophilia; venous thromboembolism

Indexed keywords

ACTIVATED PROTEIN C; ANTHRACYCLINE; AROMATASE INHIBITOR; BEVACIZUMAB; CORTICOSTEROID; DOCETAXEL; ERYTHROPOIETIN; FLUOROPYRIMIDINE; GEMCITABINE; IRINOTECAN; PEMETREXED; PLATINUM COMPLEX; PROTEIN TYROSINE KINASE INHIBITOR; THROMBIN; TRASTUZUMAB;

ADULT; AGED; ARTICLE; BREAST TUMOR; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER RECURRENCE; CANCER SURVIVAL; CONTROLLED STUDY; DISTANT METASTASIS; FEMALE; GASTROINTESTINAL TUMOR; HEAD AND NECK CANCER; HUMAN; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; MALIGNANT NEOPLASTIC DISEASE; MELANOMA; OUTPATIENT; PREDICTION; PRIMARY TUMOR; PRIORITY JOURNAL; PROTEIN FUNCTION; RISK FACTOR; SARCOMA; SOLID TUMOR; THROMBOPHILIA; UROGENITAL TRACT CANCER; VENOUS THROMBOEMBOLISM;

CHEMOTHERAPY; THROMBOPHILIA; VENOUS THROMBOEMBOLISM;

ACTIVATED PROTEIN C RESISTANCE; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; FEMALE; HUMANS; MALE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; PROTEIN C; THROMBIN; VENOUS THROMBOEMBOLISM;

EID: 84879231155     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.28104     Document Type: Article

References (25)

1. Blom JW, Doggen CJ, Osanto S, et al. Malignancies, prothrombotic mutations, and the risk of venous thrombosis. J Am Med Assoc 2005; 293: 715-22.
2. Sousou T, Khorana AA,. New insights into cancer-associated thrombosis. Arterioscler Thromb Vasc Biol 2009; 29: 316-20.
3. Di Nisio M, Ferrante N, De Tursi M, et al. Incidental venous thromboembolism in ambulatory cancer patients receiving chemotherapy. Thromb Haemost 2010; 104: 1049-54.
4. Haddad TC, Greeno EW,. Chemotherapy-induced thrombosis. Thromb Res 2006; 118: 555-68.
5. Haim N, Lanir N, Hoffman R, et al. Acquired activated protein C resistance is common in cancer patients and is associated with venous thromboembolism. Am J Med 2001; 110: 91-6.
6. Green D, Maliekel K, Sushko E, et al. Activated-protein-C resistance in cancer patients. Haemostasis 1997; 27: 112-8.
7. Soyer N, Kececi B, Eroglu Z, et al. Acquired activated protein C resistance in sarcoma patients. Blood Coagul Fibrinolysis 2012; 23: 428-33.
8. Feffer SE, Carmosino LS, Fox RL,. Acquired protein C deficiency in patients with breast cancer receiving cyclophosphamide, methotrexate, and 5-fluorouracil. Cancer 1989; 63: 1303-7.
9. Mukherjee SD, Swystun LL, Mackman N, et al. Impact of chemotherapy on thrombin generation and on the protein C pathway in breast cancer patients. Pathophysiol Haemost Thromb 2010; 37: 88-97.
10. Elice F, Fink L, Tricot G, et al. Acquired resistance to activated protein C (aAPCR) in multiple myeloma is a transitory abnormality associated with an increased risk of venous thromboembolism. Br J Haematol 2006; 134: 399-405.
11. Erman M, Abali H, Oran B, et al. Tamoxifen-induced tissue factor pathway inhibitor reduction: a clue for an acquired thrombophilic state? Ann Oncol 2004; 15: 1622-6.
12. Ferroni P, Riondino S, Portarena I, et al. Association between increased tumor necrosis factor-alpha levels and acquired activated protein C resistance in patients with metastatic colorectal cancer. Int J Colorectal Dis 2012; 27: 1561-7.
13. Negaard HF, Iversen PO, Østenstad B, et al. Increased acquired activated protein C resistance in unselected patients with hematological malignancies. J Thromb Haemost 2008; 6: 1482-7.
14. Ferroni P, Martini F, Portarena I, et al. Early changes of a novel APC-dependent thrombin generation assay during chemotherapy independently predict venous thromboembolism in cancer patients-a pilot study. Support Cancer Care 2012; 20: 2713-20.
15. Khorana AA, Kuderer NM, Culakova E, et al. Development and validation of a predictive model for chemotherapy-associated thrombosis. Blood 2008; 111: 4902-7.
16. Ferroni P, Martini F, Portarena I, et al. An APC-dependent thrombin generation assay predicts chemotherapy-associated venous thromboembolism in cancer patients. Thromb Haemost 2011; 105: 931-2.
17. Ay C, Dunkler D, Simanek R, et al. Prediction of venous thromboembolism in patients with cancer by measuring thrombin generation: results from the Vienna Cancer and Thrombosis Study. J Clin Oncol 2011; 29: 2099-103.
18. Mandalà M, Barni S, Prins M, et al. Acquired and inherited risk factors for developing venous thromboembolism in cancer patients receiving adjuvant chemotherapy: a prospective trial. Ann Oncol 2010; 21: 871-6.
19. Ferroni P, Della-Morte D, Palmirotta R, et al. Platinum based compounds and risk for cardiovascular toxicity in the elderly: role of the antioxidants in chemoprevention. Rejuvenation Res 2011; 14: 293-308.
20. Daher IN, Yeh ET,. Vascular complications of selected cancer therapies. Nat Clin Pract Cardiovasc Med 2008; 5: 797-805.
21. Barni S, Labianca R, Agnelli G, et al. Chemotherapy-associated thromboembolic risk in cancer outpatients and effect of nadroparin thromboprophylaxis: results of a retrospective analysis of the PROTECHT study. J Transl Med 2011; 9: 179-85.
22. Verso M, Agnelli G, Barni S, et al. A modified Khorana risk assessment score for venous thromboembolism in cancer patients receiving chemotherapy: the Protecht score. Intern Emerg Med 2012; 7: 291-2.
23. Moore RA, Adel N, Riedel E, et al. High incidence of thromboembolic events in patients treated with Cisplatin-based chemotherapy: a large retrospective analysis. J Clin Oncol 2011; 29: 3466-73.
24. Roselli M, Mineo TC, Basili S, et al. Vascular endothelial growth factor (VEGF-A) plasma levels in non-small cell lung cancer. Relationship with coagulation and platelet activation markers. Thromb Haemost 2003; 89: 177-84.
25. Khorana AA, Streiff MB, Farge D, et al. Venous thromboembolism prophylaxis and treatment in cancer: a consensus statement of major guidelines panels and call to action. J Clin Oncol 2009; 27: 4919-26.